Forxiga recommended in EU for patients with CKD
28 June 2021 07:05 BST Forxiga recommended for approval in the EU by CHMPfor the treatment of patients with chronic kidney disease If approved, Forxiga has the potential to change the treatment paradigmfor millions of people in the EU suffering from chronic kidney disease AstraZeneca's Forxiga (dapagliflozin) has been recommended for approval in the European Union (EU) for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes (T2D). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency based its positive